Squarepoint Ops LLC Purchases 89,253 Shares of Vera Therapeutics, Inc. $VERA

Posted by Brian Himes on Sep 12th, 2026

Squarepoint Ops LLC boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 569.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,937 shares of the company’s stock after acquiring an additional 89,253 shares during the period. Squarepoint Ops LLC’s holdings in Vera Therapeutics were worth $4,503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after buying an additional 17,907 shares during the period. Jane Street Group LLC increased its holdings in Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after buying an additional 62,678 shares during the period. JPMorgan Chase & Co. raised its stake in Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after buying an additional 262,805 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after buying an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total value of $649,720.00. Following the completion of the sale, the chief executive officer directly owned 235,244 shares in the company, valued at $8,261,769.28. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 83,250 shares of company stock valued at $3,307,800. 15.90% of the stock is owned by company insiders.

Analyst Ratings Changes

VERA has been the topic of several recent research reports. TD Cowen increased their target price on Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. Raymond James Financial reiterated a “strong-buy” rating and issued a $84.00 target price on shares of Vera Therapeutics in a report on Tuesday, August 11th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $80.15.

Get Our Latest Report on Vera Therapeutics

Vera Therapeutics Stock Up 4.3%

Shares of VERA stock opened at $35.05 on Friday. The stock’s fifty day moving average price is $35.11 and its 200 day moving average price is $37.18. Vera Therapeutics, Inc. has a 1-year low of $22.72 and a 1-year high of $56.05. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -5.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the previous year, the firm earned ($1.20) earnings per share. On average, research analysts expect that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

(Free Report)

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.